ARGX
The bull case is still alive
Wall Street is back in its favorite hobby: declaring a stock has room to run. This time it’s Argenx, with Wells Fargo and UBS both slapping 12-month price targets on the name that sit more than 40% above the current share price.
Why investors care
That doesn’t automatically mean the stock is headed straight to the moon. But when two big-name banks are singing the same tune, it can help keep sentiment warm — especially for a biotech like Argenx, where the market is always trying to handicap the next leg of growth, the next label expansion, or the next surprise.
- More upside targets can attract momentum money.
- It can also reassure existing shareholders that the Street still sees a lot of value left.
- And yes, it can make the stock a little more news-driven than usual, which is either fun or annoying depending on your cost basis.
Big picture
This isn’t a business update or a trial readout. It’s a classic analyst-vibes moment: no fresh clinical fireworks, just more confidence from the people with the spreadsheets. Sometimes that’s enough to keep a biotech name buzzing.